1Kongsakona R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo- controlled pilot study[ J ]. Int Clin Psychopharmacol, 2005, 20(5). 253 - 256
2Grabowski J, Shearer J, Merrill J, et al. Agonist - likereplacement pharmacotherapy for stimulant abuse and dependence [ J ]. Addict Behav, 2004, 29: 1439- 1464
3Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence[ J ]. Biol Psychiatry, 2005, 58:158-164
4World Health Organization (WHO). Amphetamine -type stimulants: a report from the WHO meeting on amphetamines, MDMA and other psychostimulants[ R]. Geneva: WHO, 1997
5United Nations Office on Drugs and Crime. World drug report 2005 [ OL/CD]. [2005 - 11 - 14] http: //www. unodc. org/ unodc/world_drug_report. html
6McIver C, Pointer S, Ali R, et al. Functional use of amphetamine - type stimulants amongst high - risk occupational groups in China, Nigeria, Philippines and Thailand[ M ]//A report from the WHO collaborative study on amphetamine- type stimulants. Geneva: WHO, 2002. [ DASSA monograph no. 18 ]
7Farrell M, Marsden J, Ali R, et al. Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region[J]. Addiction, 2002, 97:771 -772
8Hanson GR, Sandoval V, Riddle E, et al. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications[J]. Ann N Y Acad Sci USA, 2004, 1025: 146- 150
9Pierce R, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse[J]. Neurosci Biobehav Rev, 2006; 30:215 -238
10Sandoval V, Riddle EL, Hanson GR, et al. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine - induced dopaminergic deficits[J]. J Pharmacol Exp Ther, 2003, 304:1181 - 1187
